Details for Patent: 12,589,075
✉ Email this page to a colleague
Which drugs does patent 12,589,075 protect, and when does it expire?
Patent 12,589,075 protects AUSTEDO XR and is included in one NDA.
This patent has forty-five patent family members in twenty-seven countries.
Summary for Patent: 12,589,075
| Title: | Osmotic dosage forms comprising deutetrabenazine and methods of use thereof |
| Abstract: | Provided herein are osmotic dosage forms containing deutetrabenazine for use in the treatment of, e.g., hyperkinetic movement disorders. When orally administered to a subject on a once-daily basis, the dosage forms provide a favorable pharmacokinetic profile for the active agent indicating treatment efficacy over an extended period of time. |
| Inventor(s): | Parag Shah, Mayank Joshi, Soumen Pattanayek, Divyang Patel, Sandeep Pandita |
| Assignee: | Auspex Pharmaceuticals Inc |
| Application Number: | US18/609,809 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Device; Dosage form; |
Drugs Protected by US Patent 12,589,075
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva | AUSTEDO XR | deutetrabenazine | TABLET, EXTENDED RELEASE;ORAL | 216354-001 | Feb 17, 2023 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | A METHOD OF TREATING HUNTINGTON'S CHOREA | ⤷ Start Trial | ||||
| Teva | AUSTEDO XR | deutetrabenazine | TABLET, EXTENDED RELEASE;ORAL | 216354-001 | Feb 17, 2023 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF TARDIVE DYSKINESIA | ⤷ Start Trial | ||||
| Teva | AUSTEDO XR | deutetrabenazine | TABLET, EXTENDED RELEASE;ORAL | 216354-002 | Feb 17, 2023 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | A METHOD OF TREATING HUNTINGTON'S CHOREA | ⤷ Start Trial | ||||
| Teva | AUSTEDO XR | deutetrabenazine | TABLET, EXTENDED RELEASE;ORAL | 216354-002 | Feb 17, 2023 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF TARDIVE DYSKINESIA | ⤷ Start Trial | ||||
| Teva | AUSTEDO XR | deutetrabenazine | TABLET, EXTENDED RELEASE;ORAL | 216354-008 | Jul 1, 2024 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | A METHOD OF TREATING HUNTINGTON'S CHOREA | ⤷ Start Trial | ||||
| Teva | AUSTEDO XR | deutetrabenazine | TABLET, EXTENDED RELEASE;ORAL | 216354-008 | Jul 1, 2024 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF TARDIVE DYSKINESIA | ⤷ Start Trial | ||||
| Teva | AUSTEDO XR | deutetrabenazine | TABLET, EXTENDED RELEASE;ORAL | 216354-003 | Feb 17, 2023 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | A METHOD OF TREATING HUNTINGTON'S CHOREA | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,589,075
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 122596 | ⤷ Start Trial | |||
| Australia | 2021288087 | ⤷ Start Trial | |||
| Australia | 2023204103 | ⤷ Start Trial | |||
| Australia | 2025205457 | ⤷ Start Trial | |||
| Brazil | 112022025185 | ⤷ Start Trial | |||
| Canada | 3186425 | ⤷ Start Trial | |||
| Canada | 3257711 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
